Provention Bio Inc. (PRVB) Announces Proposed 5.5M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- S&P 500 ends higher as investors await tech earnings
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Provention Bio Inc. (PRVB) Prices 6.6M Share Common Offering at $14.50/Sh
June 18, 2020 5:58 AM EDTProvention Bio, Inc., (NASDAQ: PRVB) today announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share. Gross proceeds to Provention Bio from the offering are expected to be $95.7 million, before deducting underwriting discounts... More
Provention Bio Inc. (PRVB) PT Raised to $26 at H.C. Wainwright
June 16, 2020 6:34 AM EDTH.C. Wainwright analyst Raghuram Selvaraju raised the price target on Provention Bio Inc. (NASDAQ: PRVB) to $26.00 (from $20.00) while maintaining a Buy rating.... More
Provention Bio Inc. (PRVB) Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients
June 15, 2020 12:09 PM EDTProvention Bio, Inc. (Nasdaq: PRVB) announced extended follow-up data showing a single 14-day course of teplizumab (PRV-031) significantly delayed the onset of insulin-dependent type 1 diabetes (T1D) in presymptomatic patients by a median of approximately three years compared to placebo. These new data from the pivotal "At-Risk" TN-10 Study add one year to the two-year median delay that was previously reported in the New England Journal of Medicine and presented at last year's American Diabetes Association's (ADA's) Scientific Sessions. Teplizumab, Provention's lead drug candidate, is an anti-CD3 monoclonal antibody in development for the... More
Provention Bio Inc. (PRVB) gains on talk of positive diabetes data
June 15, 2020 11:31 AM EDTProvention Bio Inc. (NASDAQ: PRVB) gains on talk of positive diabetes data.
... More